ONESOURCE1,548.10

Onesource Specialty Pharma Ltd.

· Pharma & Health
₹ CrorePeersSTARDIVISLABGLANDPFIZERPOLYMEDRAINBOWKIMSJUBLPHARMAMcap ₹17,744 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth-1.6
EBITDA Growth-34.8
EBIT Growth-87.0
Net Income Growth-310.7
EPS Growth-295.1
Total Assets Growth+8.7
Total Equity Growth-0.8
Cash from Operations Growth+139.6
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.